iDose TR

Indicated For

open-angle glaucoma, ocular hypertension

About This Medication

# iDose TR Patient Savings Program Guide: How to Get iDose TR at Low or No Cost iDose TR (travoprost intracameral implant) is a long-lasting treatment implanted in the eye by a doctor to help lower eye pressure in people with open-angle glaucoma or ocular hypertension, potentially freeing you from daily eye drops.[5][10] The **iDose TR Patient Savings Program** from Glaukos Corporation helps eligible commercially insured patients pay **as little as $0** for their out-of-pocket costs for the implant.[1][7] ## About iDose TR **iDose TR** is a tiny, anchored implant placed directly into the eye's anterior chamber during a quick in-office procedure by a specially trained eye doctor.[1][5] It continuously releases travoprost, a prostaglandin analog, for up to **3 years** to control intraocular pressure (IOP)—a key factor in open-angle glaucoma (OAG) and ocular hypertension (OHT).[5] In clinical trials: - **8 out of 10 patients** were completely free of prescription eye drops at 12 months.[4][5] - It showed non-inferiority to daily timolol drops through 3 months, with long-term IOP control.[5] Unlike daily drops, iDose TR provides **24/7 adherence** without the hassle of remembering doses, instilling drops, or dealing with side effects like blurred vision.[4][5] It's dispensed exclusively through **Orsini Specialty Pharmacy**, which handles benefits checks and prior authorizations.[2] **Important**: iDose TR is a **procedure**, not a take-home pill or drop. Your doctor administers it, and costs may include the implant plus procedure fees (program covers only implant out-of-pocket).[1][8] ## Who Qualifies for the Program? This savings program is **not income-based**—it's designed for **commercially insured patients** with an out-of-pocket responsibility for iDose TR.[1] Key requirements:[1] - **Commercial (private) insurance** only—no Medicare, Medicaid, VA, DoD, TRICARE, or other government programs.[1][8] - Live in the **US or US territories**. - **Age 18+** on procedure date. - iDose TR prescribed by a **US-trained iDose TR physician** for FDA-approved use (OAG or OHT).[1][5] - **Out-of-pocket costs** shown on your insurance **Explanation of Benefits (EOB)** or remittance.[1] - Procedure date **on or before December 31, 2026**.[1] - Submit application + EOB **within 180 days** of procedure.[1] The program covers **one iDose TR implant per eye** and reduces your copay/coinsurance to **$0** (max savings per implant; excludes procedure/admin fees).[1][7][8] ## Income Eligibility **No income limits apply.** This program focuses on insurance type and procedure details, not household income or FPL percentage.[1] It's available regardless of finances as long as you meet the commercial insurance and other criteria above. | Household Size | Income Threshold | Notes | |----------------|------------------|--------| | Individual | None | Commercial insurance required[1] | | Couple | None | No FPL limits[1] | | Family of 3 | None | Focus on EOB/proof of out-of-pocket[1] | | Family of 4 | None | Expires 12/31/2026[1] | ## Insurance Requirements **Commercial insurance only.**[1][8] - **Exclusions**: Medicare, Medicaid, Medigap, VA, DoD, TRICARE, or any federal/state government program.[1][8] - Your plan must show **out-of-pocket responsibility** for iDose TR on the EOB.[1] - Orsini Specialty Pharmacy verifies benefits and handles prior authorizations (PA).[2][7] - Some payers require **specialty pharmacy** (SP) like Orsini instead of buy-and-bill.[2][7] Glaukos Patient Services (GPS) can help navigate coverage: call (888) 441-2519.[1][4] ## Step-by-Step Application Process 1. **Get iDose TR Procedure**: Visit a US iDose TR-trained physician. They confirm it's right for your OAG/OHT and handle prescribing.[1] 2. **Receive EOB**: After procedure, get your **Explanation of Benefits (EOB)** from insurance showing your out-of-pocket for iDose TR. **Required to apply.**[1] 3. **Apply for Savings**: - Visit [iDose TR Patient Savings Program page](https://www.idosetr.com/patient-savings-program/) or call **(888) 441-2519**.[1] - Submit application + EOB **within 180 days** of procedure date.[1] - Orsini may be involved for enrollment if using SP.[2] 4. **Processing**: Allow **6-8 weeks**. You'll get confirmation.[1] 5. **Receive Benefit**: Program pays your eligible out-of-pocket directly (up to $0 copay).[1][7] **Tip**: Ask your doctor's office or GPS for help with EOB and forms.[4] ## Timeline and Delivery - **EOB Arrival**: 2-4 weeks post-procedure (varies by insurer). - **Application Window**: 180 days from procedure.[1] - **Processing**: **6-8 weeks** after submission.[1] - **Total Time**: Up to 3 months from procedure to savings. - **Delivery**: Savings applied to your cost-share; iDose TR is already implanted. No shipment—it's a one-time procedural implant.[1][5] Program valid only for procedures **by 12/31/2026**.[1] ## Alternatives if Denied or Ineligible - **Government Insurance**: Contact Glaukos for charitable donations (equal units pledged per sale).[3] Or check general glaucoma aid like BrightFocus resources.[9] - **No Coverage/High Costs**: Discuss alternatives with doctor: topical travoprost drops, other implants (e.g., Durysta), lasers, or surgery.[5][9] - **Appeals**: Work with doctor's office for PA/appeals; include medical necessity (IOP history, prior treatments).[7] - **Other Aid**: AbbVie programs for similar glaucoma meds, or general patient assistance foundations.[9] - **Orsini Support**: Call 847-378-5982 for benefit help.[2] ## Disclaimer This guide summarizes the iDose TR Patient Savings Program based on available info as of 2026.[1][7] Eligibility, benefits, and terms can change—**always verify with Glaukos at (888) 441-2519** or idosetr.com.[1] Program doesn't cover procedure fees, office visits, or non-iDose TR costs.[8] Not health/financial advice; consult your doctor/insurer. Glaukos reserves right to modify/terminate program.[1][8] See full terms at idosetr.com/terms-conditions.[8] (Word count: 1028)

Program information last verified: March 30, 2026